Clinical trial · Interventional
68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study
FAST HOC-FAPI PET for Staging of High-Grade Serous Ovarian Cancer .
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260929-000001
Summary
Brief summary (as posted)
The investigator will use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data are gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre. The purpose of this study is to find out if the use of 68Ga-PNT6555 (FAPI) PET-CT will improve the assessment of disease extent as compared to routine CT scans.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| High Grade Serous Ovarian Cancer (HGSOC) | High-Grade Serous Ovarian Cancer | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FAPI PET CT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- high-grade epithelial ovarian cancers.
- description
- individuals who have been diagnosed or are suspected to have high-grade serous ovarian cancers (HGSOC). They must have had a CT scan of their abdomen and pelvis within 6 weeks before enrolling in the study and be at clinical stage III or IV.
- interventionNames
- Radiation: FAPI PET CT
Primary outcomes (2)
- measure
- FAPI positivity
- timeFrame
- through study completion, an average of 1 year
- description
- A lesion will be considered abnormal when focal tracer accumulation is greater than background activity and cannot be attributed to a physiological or benign entity.FAPI tumour volumes will be correlated with clinical outcome measures including: 1. Achievement of optimal or complete cytoreduction; 2. Progression-free survival (PFS); 3. Overall survival (OS).
- measure
- Quantitative parameters
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients will be eligible for inclusion in this study if they meet the following criteria: * Age ≥18 years. * Cytological or histological diagnosis of HGSOC, or clinical suspicion of HGSOC based on symptoms, physical exam, tumour markers, and imaging findings. * Clinical stage III or IV, being considered for PCS or NACT. * Contrast-enhanced CT abdomen and pelvis within 6 weeks of PET (prior to enrolment). Exclusion Criteria: Patients will be ineligible to participate in this study if they meet any of the following criteria: * Inability to provide informed consent. * Contraindications for PET examination as per institutional safety guidelines, including but not limited to pregnancy, or inability to lie still for PET examination. * Evidence of the following epithelial ovarian cancer histological subtypes: Mucinous, low-grade serous, low-grade endometrioid, and low-malignant potential tumours. * Non-ovarian advanced gynecological malignancy
References
Publications (0)
Data not yet available